Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M172,577Revenue (TTM) $M39,444Net Margin (%)13.0Altman Z-Score3.4
Enterprise Value $M185,118EPS (TTM) $1.8Operating Margin %18.7Piotroski F-Score7
P/E(ttm)34.5Beneish M-Score-2.7Pre-tax Margin (%)16.1Higher ROA y-yN
Price/Book4.010-y EBITDA Growth Rate %4.7Quick Ratio1.4Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %9.2Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow18.1y-y EBITDA Growth Rate %-39.4ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %2.9PEG3.8ROE % (ttm)11.5Less Shares Outstanding y-yY
Payout Ratio %101Shares Outstanding M2,765ROIC % (ttm)10.8Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJoel Greenblatt 2016-06-30 Reduce-0.42%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -56.73%540,222
MRKT Rowe Price Equity Income Fund 2016-06-30 Reduce-0.3%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -25.58%3,500,000
MRKVanguard Health Care Fund 2016-06-30 Reduce-0.26%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -4.57%46,499,820
MRKKahn Brothers 2016-06-30 Reduce-0.2%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -2.08%964,925
MRKRichard Pzena 2016-06-30 Add0.18%$52.91 - $57.68
($55.73)
$ 62.4112%Add 53.62%1,415,390
MRKCharles Brandes 2016-06-30 Reduce-0.08%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -3.60%2,891,914
MRKKen Fisher 2016-06-30 Add0.01%$52.91 - $57.68
($55.73)
$ 62.4112%Add 0.91%6,759,345
MRKTom Gayner 2016-06-30 Buy 0.01%$52.91 - $57.68
($55.73)
$ 62.4112%New holding5,600
MRKDodge & Cox 2016-06-30 Reduce-0.01%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -0.70%24,372,814
MRKBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Reduce-0.01%$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -0.55%26,516,070
MRKFirst Eagle Investment 2016-06-30 Reduce$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -51.58%7,790
MRKMario Gabelli 2016-06-30 Reduce$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -3.93%113,505
MRKRuane Cunniff 2016-06-30 Reduce$52.91 - $57.68
($55.73)
$ 62.4112%Reduce -18.66%3,981
MRKRichard Pzena 2016-03-31 Buy 0.3%$48.59 - $53.32
($51.31)
$ 62.4122%New holding921,365
MRKJoel Greenblatt 2016-03-31 Add0.29%$48.59 - $53.32
($51.31)
$ 62.4122%Add 65.71%1,248,557
MRKKahn Brothers 2016-03-31 Reduce-0.24%$48.59 - $53.32
($51.31)
$ 62.4122%Reduce -2.52%985,419
MRKT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.22%$48.59 - $53.32
($51.31)
$ 62.4122%Reduce -16.17%4,702,900
MRKVanguard Health Care Fund 2016-03-31 Reduce-0.18%$48.59 - $53.32
($51.31)
$ 62.4122%Reduce -3.46%48,728,100
MRKNWQ Managers 2016-03-31 Sold Out -0.06%$48.59 - $53.32
($51.31)
$ 62.4122%Sold Out0
MRKCharles Brandes 2016-03-31 Reduce-0.01%$48.59 - $53.32
($51.31)
$ 62.4122%Reduce -0.42%3,000,058
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schechter Adam HEVP & Pres-Global Human Health 2016-09-01Sell39,200$62.61-0.32view
Golestani ClarkEVP & Chief Info Officer 2016-08-10Sell3,000$63.03-0.98view
FRAZIER KENNETH CChairman, President & CEO 2016-08-05Sell392,000$61.810.97view
GRADDICK WEIR MIRIAN MExe V-P, HR 2016-07-05Sell45,000$57.997.62view
FRAZIER KENNETH CChairman, President & CEO 2016-07-05Sell60,000$587.6view
Schechter Adam HEVP & Pres-Global Human Health 2016-07-01Sell50,000$57.698.18view
GRADDICK WEIR MIRIAN MExe V-P, HR 2016-07-01Sell30,000$57.498.56view
Golestani ClarkEVP & Chief Info Officer 2016-05-20Sell39,877$54.7913.91view
Holston Michael JEVP, General Counsel 2016-05-10Sell100,021$54.514.51view
FRAZIER KENNETH CChairman, President & CEO 2016-04-14Sell131,040$56.1111.23view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about MRK:

Articles On GuruFocus.com
Deutsche Bank's Losses Affecting the Market on Thursday Sep 29 2016 
Stocks Higher With OPEC Agreement Sep 29 2016 
Investors Reward Merck Despite Flat Revenue Growth Sep 27 2016 
US Indexes Gain Ahead of Central Bank Announcements Sep 20 2016 
Sanofi Sues Merck Over Patent Infringement Sep 20 2016 
Stocks Trade Lower Monday With Global Central Bank Uncertainty Sep 19 2016 
Kahn Brothers Trims Pfizer, Citigroup Sep 16 2016 
US Market Indexes Mixed With Increased Uncertainty Sep 14 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Slowing Economic Growth Has Stocks Trading Lower Sep 07 2016 

More From Other Websites
Novo Nordisk Is Number One Player in Diabetes Care Market in 2016 Sep 30 2016
Deutsche Bank's Losses Affecting the Market on Thursday Sep 29 2016
Dow closes down nearly 200 points on Deutsche Bank, Fed concerns Sep 29 2016
U.S. Stocks Sell Off On Deutsche Bank Worries, But Oil Plays Surge Sep 29 2016
Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of... Sep 29 2016
Merck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States Sep 29 2016
Merck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States Sep 29 2016
Merck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 Sep 28 2016
MSD Animal Health Demonstrates Commitment to Eliminate Rabies Worldwide with Donation of More Than... Sep 28 2016
Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with... Sep 28 2016
Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with... Sep 28 2016
Blockbuster biotech deal coming? Sep 27 2016
Gilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck Sep 27 2016
Mylan’s Wheelhouse Impressive, Includes a New FDA Accepted Drug Sep 27 2016
Wall Street Sells Off on Worries Over Clinton-Trump Showdown Sep 26 2016
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies Sep 26 2016
[$$] Merck’s Keytruda Finds Fast Entry Into China Via Medical-Tourism Push Sep 23 2016
You’ve Heard about the EpiPen Debacle, but Have You Heard This? Sep 23 2016
[$$] Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push Sep 23 2016
Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25 Sep 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)